Scientists discover ‘death complex’ that could worsen Alzheimer’s - and how to fight it
AOL.com • • health
Key Points:
- Researchers from Heidelberg University and Shandong University identified a "death switch" involving the interaction between NMDA receptors and TRPM4 ion channels that triggers brain cell death and contributes to Alzheimer's disease progression.
- The team tested an experimental drug, FP802, which blocks this harmful interaction, successfully slowing neurodegeneration, preserving cognitive functions, and reducing amyloid beta deposits in a mouse model of Alzheimer's.
- Unlike traditional treatments targeting amyloid formation, FP802 works by inhibiting a downstream cellular mechanism responsible for nerve cell death and amyloid accumulation.
- The researchers suggest FP802 could potentially be applied to other neurodegenerative diseases like ALS, as the same protein interaction is implicated.
- Despite promising results, further pharmacological development, toxicology testing, and clinical trials are necessary before FP802 can be considered for human use.
